Identification

Name
Atorvastatin
Accession Number
DB01076  (APRD00055)
Type
Small Molecule
Groups
Approved
Description

Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.

Structure
Thumb
Synonyms
  • atorvastatina
  • atorvastatine
  • atorvastatinum
Product Ingredients
IngredientUNIICASInChI Key
Atorvastatin calciumC0GEJ5QCSO134523-03-8FQCKMBLVYCEXJB-MNSAWQCASA-L
Atorvastatin calcium trihydrate48A5M73Z4Q344423-98-9SHZPNDRIDUBNMH-NIJVSVLQSA-L
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AtorvastatinTablet80 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
AtorvastatinTablet80 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
AtorvastatinTablet10 mgOralRanbaxy Inc.Not applicableNot applicableCanada
AtorvastatinTablet40 mgOralPro Doc Limitee2010-05-21Not applicableCanada
AtorvastatinTablet40 mgOralSanis Health Inc2010-05-27Not applicableCanada
AtorvastatinTablet80 mgOralRatiopharm Inc Division Of Teva Canada Limited2010-05-192013-06-27Canada
AtorvastatinTablet10 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
AtorvastatinTablet80 mgOralApotex Corporation2013-01-07Not applicableCanada
AtorvastatinTablet20 mgOralSivem Pharmaceuticals Ulc2012-06-26Not applicableCanada
AtorvastatinTablet10 mgOralApotex Corporation2013-01-07Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-atorvastatin CalciumTablet80 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-atorvastatin CalciumTablet10 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-atorvastatin CalciumTablet40 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-atorvastatin CalciumTablet20 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Apo-atorvastatinTablet40 mgOralApotex Corporation2010-05-19Not applicableCanada
Apo-atorvastatinTablet20 mgOralApotex Corporation2010-05-19Not applicableCanada
Apo-atorvastatinTablet80 mgOralApotex Corporation2010-05-19Not applicableCanada
Apo-atorvastatinTablet10 mgOralApotex Corporation2010-05-19Not applicableCanada
Atorvastatin CalciumTablet, film coated80 mg/1OralA S Medication Solutions2013-09-192017-06-20Us
Atorvastatin CalciumTablet, film coated80 mg/1OralNu Care Pharmaceuticals,inc.2016-08-04Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Amlodipine besylate and Atorvastatin calciumAtorvastatin calcium (40 mg/1) + Amlodipine besylate (5 mg/1)Tablet, film coatedOralDr Reddy's Laboratories2014-03-17Not applicableUs43598 0316 30 nlmimage10 f63ffb6f
Amlodipine Besylate and Atorvastatin CalciumAtorvastatin calcium trihydrate (10 mg/1) + Amlodipine besylate (5 mg/1)Tablet, film coatedOralRanbaxy Inc.2011-12-062018-03-01Us
Amlodipine besylate and atorvastatin calciumAtorvastatin calcium trihydrate (40 mg/1) + Amlodipine besylate (2.5 mg/1)Tablet, film coatedOralMylan Pharmaceuticals2013-02-14Not applicableUs
Amlodipine besylate and Atorvastatin calciumAtorvastatin calcium trihydrate (10 mg/1) + Amlodipine besylate (5 mg/1)Tablet, film coatedOralGreenstone, Llc2014-04-04Not applicableUs
Amlodipine besylate and atorvastatin calciumAtorvastatin calcium trihydrate (10 mg/1) + Amlodipine besylate (10 mg/1)Tablet, film coatedOralMylan Pharmaceuticals2014-09-03Not applicableUs
Amlodipine Besylate and Atorvastatin CalciumAtorvastatin calcium trihydrate (80 mg/1) + Amlodipine besylate (5 mg/1)Tablet, film coatedOralRanbaxy Inc.2011-12-062018-03-01Us
Amlodipine Besylate and Atorvastatin CalciumAtorvastatin calcium trihydrate (80 mg/1) + Amlodipine besylate (10 mg/1)Tablet, film coatedOralRanbaxy Inc.2011-12-062018-03-01Us
Amlodipine besylate and Atorvastatin calciumAtorvastatin calcium trihydrate (20 mg/1) + Amlodipine besylate (10 mg/1)Tablet, film coatedOralGreenstone, Llc2014-04-04Not applicableUs
Amlodipine besylate and Atorvastatin calciumAtorvastatin calcium (10 mg/1) + Amlodipine besylate (10 mg/1)Tablet, film coatedOralDr Reddy's Laboratories2014-03-17Not applicableUs
Amlodipine besylate and Atorvastatin calciumAtorvastatin calcium trihydrate (40 mg/1) + Amlodipine besylate (5 mg/1)Tablet, film coatedOralGreenstone, Llc2014-04-04Not applicableUs59762 6722 01 nlmimage10 dc3fee1f
International/Other Brands
Atogal (Ingers (Czech Republic)) / Cardyl (Pfizer (Spain)) / Faboxim (Fabop (Argentina)) / Hipolixan (Pasteur (Chile)) / Lipotropic (Drugtech (Chile)) / Liprimar (Pfizer (Hungary, Ukraine), Goedecke (Russia)) / Lowden (Saval (Chile)) / Normalip (Quesada (Argentina)) / Sincol (Indeco (Argentina)) / Sortis (Pfizer (Austria, Czech Republic, Germany, Hungary, Poland, Portugal, Switzerland), Godecke (Germany), Parke, Davis (Germany)) / Torvacard (Zentiva (Czech Republic, Hungary, Poland, Russia, Ukraine)) / Torvast (Pfizer (Italy)) / Totalip (Guidotti (Italy)) / Tulip (Lek (Czech Republic, Russia), Wermar (Mexico), Sandoz (Poland, Ukraine), Pharmacia (Spain)) / Vastina (Penn (Argentina)) / Xanator (Sieger (Greece)) / Xarator (Parke, Davis (Italy)) / Zurinel (Prater (Chile))
Categories
UNII
A0JWA85V8F
CAS number
134523-00-5
Weight
Average: 558.6398
Monoisotopic: 558.253000445
Chemical Formula
C33H35FN2O5
InChI Key
XUKUURHRXDUEBC-KAYWLYCHSA-N
InChI
InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
IUPAC Name
(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
SMILES
CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1

Pharmacology

Indication

May be used as primary prevention in individuals with multiple risk factors for coronary heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of myocardial infarction (MI), stroke, angina, and revascularization procedures. May be used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia, homozygous familial hypercholesterolemia, primary dysbetalipoproteinemia, and/or hypertriglyeridemia as an adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and triglyceride concentrations, while increasing high-density lipoprotein cholesterol (HDL-C) levels.

Associated Conditions
Pharmacodynamics

Atorvastatin, a selective, competitive HMG-CoA reductase inhibitor, is used to lower serum total and LDL cholesterol, apoB, and triglyceride levels while increasing HDL cholesterol. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, atorvastatin reduces the risk of cardiovascular morbidity and mortality. Atorvastatin has a unique structure, long half-life, and hepatic selectivity, explaining its greater LDL-lowering potency compared to other HMG-CoA reductase inhibitors.

Mechanism of action

Atorvastatin selectively and competitively inhibits the hepatic enzyme HMG-CoA reductase. As HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate in the cholesterol biosynthesis pathway, this results in a subsequent decrease in hepatic cholesterol levels. Decreased hepatic cholesterol levels stimulates upregulation of hepatic LDL-C receptors which increases hepatic uptake of LDL-C and reduces serum LDL-C concentrations.

TargetActionsOrganism
A3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitor
Human
NDipeptidyl peptidase 4
inhibitor
Human
UAryl hydrocarbon receptor
agonist
Human
Absorption

Atorvastatin is rapidly absorbed after oral administration with maximum plasma concentrations achieved in 1 to 2 hours. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic bioavailability is due to presystemic clearance by gastrointestinal mucosa and first-pass metabolism in the liver.

Volume of distribution

381 L

Protein binding

>98% bound to plasma proteins

Metabolism

Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. CYP3A4 is also involved in the metabolism of atorvastatin.

Route of elimination

Eliminated primarily in bile after hepatic and/or extrahepatic metabolism. Does not appear to undergo significant enterohepatic recirculation. Less than 2% of the orally administered dose is recovered in urine.

Half life

14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites

Clearance
Not Available
Toxicity

Generally well-tolerated. Side effects may include myalgia, constipation, asthenia, abdominal pain, and nausea. Other possible side effects include myotoxicity (myopathy, myositis, rhabdomyolysis) and hepatotoxicity. To avoid toxicity in Asian patients, lower doses should be considered.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Kinesin-like protein KIF6---(C;C) / (C;T)C AlleleEffect Directly StudiedPatients with this genotype have a greater reduction in risk of a major cardiovascular event with high dose atorvastatin.Details
3-hydroxy-3-methylglutaryl-coenzyme A reductase---(A;T)T AlleleEffect Directly StudiedPatients with this genotype have a lesser reduction in LDL cholesterol with atorvastatin.Details
Cytochrome P450 3A4CYP3A4*1B(G;G) / (A;G)A > GEffect Directly StudiedPatients with this genotype have an greater reduction in LDL cholesterol with atorvastatin.Details

Interactions

Drug Interactions
DrugInteractionDrug group
6-Deoxyerythronolide BThe risk or severity of rhabdomyolysis can be increased when 6-Deoxyerythronolide B is combined with Atorvastatin.Experimental
AbafunginThe risk or severity of myopathy can be increased when Abafungin is combined with Atorvastatin.Investigational
AbirateroneThe serum concentration of Atorvastatin can be increased when it is combined with Abiraterone.Approved
AcetaminophenThe serum concentration of Atorvastatin can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Atorvastatin.Approved, Vet Approved
AcetohexamideAtorvastatin may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe risk or severity of adverse effects can be increased when Acetyl sulfisoxazole is combined with Atorvastatin.Approved, Vet Approved
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Atorvastatin.Approved, Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Atorvastatin.Approved
AlbaconazoleThe risk or severity of myopathy can be increased when Albaconazole is combined with Atorvastatin.Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Atorvastatin.Approved
AlmasilateThe serum concentration of Atorvastatin can be decreased when it is combined with Almasilate.Approved, Experimental
AloglutamolThe serum concentration of Atorvastatin can be decreased when it is combined with Aloglutamol.Approved
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Atorvastatin.Approved, Illicit, Investigational
AluminiumThe serum concentration of Atorvastatin can be decreased when it is combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe serum concentration of Atorvastatin can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Atorvastatin can be decreased when it is combined with Aluminium glycinate.Experimental
AmbroxolThe risk or severity of adverse effects can be increased when Ambroxol is combined with Atorvastatin.Approved, Investigational
AmiodaroneThe serum concentration of Atorvastatin can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineThe serum concentration of Atorvastatin can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Atorvastatin.Approved, Investigational
Amphotericin BThe risk or severity of rhabdomyolysis can be increased when Amphotericin B is combined with Atorvastatin.Approved, Investigational
AmprenavirThe risk or severity of adverse effects can be increased when Amprenavir is combined with Atorvastatin.Approved, Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Atorvastatin.Approved, Investigational
ApalutamideThe serum concentration of Atorvastatin can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe risk or severity of adverse effects can be increased when Aprepitant is combined with Atorvastatin.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Atorvastatin.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Atorvastatin.Approved, Investigational
AstemizoleThe risk or severity of adverse effects can be increased when Astemizole is combined with Atorvastatin.Approved, Withdrawn
AsunaprevirThe serum concentration of Atorvastatin can be increased when it is combined with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe risk or severity of adverse effects can be increased when Atazanavir is combined with Atorvastatin.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Atorvastatin.Approved
AVE9633The risk or severity of rhabdomyolysis can be increased when AVE9633 is combined with Atorvastatin.Investigational
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Atorvastatin.Approved
AzithromycinThe serum concentration of Atorvastatin can be increased when it is combined with Azithromycin.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Benazepril.Approved, Investigational
Benzyl alcoholThe serum concentration of Atorvastatin can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Atorvastatin can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Atorvastatin.Approved, Vet Approved
BexaroteneThe serum concentration of Atorvastatin can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateBezafibrate may increase the myopathic rhabdomyolysis activities of Atorvastatin.Approved, Investigational
BicalutamideThe risk or severity of adverse effects can be increased when Bicalutamide is combined with Atorvastatin.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Atorvastatin.Approved, Investigational
Bismuth subcitrate potassiumThe serum concentration of Atorvastatin can be decreased when it is combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateThe serum concentration of Atorvastatin can be decreased when it is combined with Bismuth subnitrate.Approved
BoceprevirThe serum concentration of Atorvastatin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Atorvastatin.Approved, Investigational
BosentanThe metabolism of Atorvastatin can be increased when combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Atorvastatin.Approved
Brefeldin AThe risk or severity of rhabdomyolysis can be increased when Brefeldin A is combined with Atorvastatin.Experimental
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Atorvastatin.Approved, Investigational
BrigatinibThe serum concentration of Atorvastatin can be decreased when it is combined with Brigatinib.Approved, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Atorvastatin.Approved, Investigational
Bryostatin 1The risk or severity of rhabdomyolysis can be increased when Bryostatin 1 is combined with Atorvastatin.Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Atorvastatin.Approved, Illicit, Investigational, Vet Approved
ButoconazoleThe risk or severity of myopathy can be increased when Butoconazole is combined with Atorvastatin.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Atorvastatin.Approved
CaffeineThe serum concentration of Atorvastatin can be increased when it is combined with Caffeine.Approved
Calcium silicateThe serum concentration of Atorvastatin can be decreased when it is combined with Calcium silicate.Experimental
CandicidinThe risk or severity of rhabdomyolysis can be increased when Candicidin is combined with Atorvastatin.Withdrawn
CandoxatrilThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Capsaicin is combined with Atorvastatin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Captopril.Approved
CarbamazepineThe serum concentration of Atorvastatin can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbomycinThe risk or severity of adverse effects can be increased when Carbomycin is combined with Atorvastatin.Vet Approved
CarbutamideAtorvastatin may increase the hypoglycemic activities of Carbutamide.Experimental
CarvedilolThe serum concentration of Atorvastatin can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Atorvastatin.Approved
CelecoxibThe metabolism of Atorvastatin can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe risk or severity of adverse effects can be increased when Ceritinib is combined with Atorvastatin.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Cerivastatin is combined with Atorvastatin.Approved, Withdrawn
CethromycinThe risk or severity of rhabdomyolysis can be increased when Cethromycin is combined with Atorvastatin.Investigational
ChloramphenicolThe risk or severity of adverse effects can be increased when Chloramphenicol is combined with Atorvastatin.Approved, Vet Approved
ChlorpropamideAtorvastatin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Atorvastatin.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Atorvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Atorvastatin.Approved, Investigational
Cimicifuga racemosaThe risk or severity of adverse effects can be increased when Cimicifuga racemosa is combined with Atorvastatin.Approved, Experimental
CiprofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofibrate is combined with Atorvastatin.Approved, Investigational
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Atorvastatin.Approved, Investigational
CisaprideThe risk or severity of adverse effects can be increased when Cisapride is combined with Atorvastatin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Atorvastatin can be increased when it is combined with Clarithromycin.Approved
ClofazimineThe risk or severity of adverse effects can be increased when Clofazimine is combined with Atorvastatin.Approved, Investigational
ClomifeneThe risk or severity of adverse effects can be increased when Clomifene is combined with Atorvastatin.Approved, Investigational
ClotiazepamThe risk or severity of adverse effects can be increased when Clotiazepam is combined with Atorvastatin.Approved, Illicit
ClotrimazoleThe risk or severity of myopathy can be increased when Clotrimazole is combined with Atorvastatin.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Atorvastatin.Approved
CobicistatThe serum concentration of Atorvastatin can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Atorvastatin.Approved, Illicit
ColchicineThe risk or severity of adverse effects can be increased when Colchicine is combined with Atorvastatin.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Atorvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Atorvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Coltuximab ravtansineThe risk or severity of rhabdomyolysis can be increased when Coltuximab ravtansine is combined with Atorvastatin.Investigational
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Atorvastatin.Approved, Investigational
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Atorvastatin.Approved, Investigational
CrisaboroleThe metabolism of Atorvastatin can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe risk or severity of adverse effects can be increased when Crizotinib is combined with Atorvastatin.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Atorvastatin.Approved, Investigational
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Atorvastatin.Approved, Investigational
CyclosporineThe excretion of Atorvastatin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Atorvastatin can be increased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Atorvastatin.Approved
DabrafenibThe serum concentration of Atorvastatin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Atorvastatin can be increased when it is combined with Daclatasvir.Approved, Investigational
DalfopristinThe risk or severity of adverse effects can be increased when Dalfopristin is combined with Atorvastatin.Approved
DanazolThe risk or severity of adverse effects can be increased when Danazol is combined with Atorvastatin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Atorvastatin.Approved
DaptomycinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Daptomycin.Approved, Investigational
DarunavirThe risk or severity of adverse effects can be increased when Darunavir is combined with Atorvastatin.Approved
DasabuvirThe serum concentration of Atorvastatin can be increased when it is combined with Dasabuvir.Approved
DasatinibThe risk or severity of adverse effects can be increased when Dasatinib is combined with Atorvastatin.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Atorvastatin.Approved
DeferasiroxThe serum concentration of Atorvastatin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Delapril.Investigational
DelavirdineThe risk or severity of adverse effects can be increased when Delavirdine is combined with Atorvastatin.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Atorvastatin.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Atorvastatin.Approved, Investigational, Vet Approved
DexniguldipineThe serum concentration of Atorvastatin can be increased when it is combined with Dexniguldipine.Experimental
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Atorvastatin.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe serum concentration of Atorvastatin can be increased when it is combined with Dexverapamil.Experimental
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Atorvastatin.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe excretion of Atorvastatin can be decreased when combined with Diclofenac.Approved, Vet Approved
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Diethylstilbestrol is combined with Atorvastatin.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Atorvastatin.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Atorvastatin.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Atorvastatin.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Atorvastatin.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Atorvastatin.Approved, Investigational
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Atorvastatin.Approved, Investigational
Dimethyl sulfoxideThe risk or severity of adverse effects can be increased when Dimethyl sulfoxide is combined with Atorvastatin.Approved, Vet Approved
DirithromycinThe risk or severity of rhabdomyolysis can be increased when Dirithromycin is combined with Atorvastatin.Approved, Investigational
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Atorvastatin.Approved, Investigational
DoramectinThe risk or severity of rhabdomyolysis can be increased when Doramectin is combined with Atorvastatin.Vet Approved
DoxazosinThe serum concentration of Atorvastatin can be increased when it is combined with Doxazosin.Approved
DoxorubicinThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Atorvastatin.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Atorvastatin.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Atorvastatin.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of adverse effects can be increased when Dronedarone is combined with Atorvastatin.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Atorvastatin.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Atorvastatin.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Atorvastatin.Approved, Investigational
EfinaconazoleThe risk or severity of myopathy can be increased when Efinaconazole is combined with Atorvastatin.Approved
ElbasvirThe risk or severity of adverse effects can be increased when Elbasvir is combined with Atorvastatin.Approved
EltrombopagThe serum concentration of Atorvastatin can be increased when it is combined with Eltrombopag.Approved
EmopamilThe serum concentration of Atorvastatin can be increased when it is combined with Emopamil.Experimental
EnalaprilThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Enalaprilat.Approved
EnasidenibThe risk or severity of adverse effects can be increased when Enasidenib is combined with Atorvastatin.Approved, Investigational
EnzalutamideThe serum concentration of Atorvastatin can be decreased when it is combined with Enzalutamide.Approved
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Atorvastatin.Approved, Vet Approved
EpofolateThe risk or severity of rhabdomyolysis can be increased when Epofolate is combined with Atorvastatin.Investigational
Epothilone DThe risk or severity of rhabdomyolysis can be increased when Epothilone D is combined with Atorvastatin.Experimental, Investigational
EprinomectinThe risk or severity of rhabdomyolysis can be increased when Eprinomectin is combined with Atorvastatin.Vet Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Atorvastatin.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Atorvastatin.Approved
ErlotinibThe risk or severity of adverse effects can be increased when Erlotinib is combined with Atorvastatin.Approved, Investigational
ErythromycinThe serum concentration of Atorvastatin can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Atorvastatin.Approved, Investigational, Vet Approved
EthanolThe risk or severity of myopathy and rhabdomyolysis can be increased when Ethanol is combined with Atorvastatin.Approved
Ethinyl EstradiolThe serum concentration of Atorvastatin can be decreased when it is combined with Ethinyl Estradiol.Approved
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with Atorvastatin.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Atorvastatin.Approved, Investigational
EtravirineThe serum concentration of Atorvastatin can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Atorvastatin.Approved
EzetimibeThe risk or severity of adverse effects can be increased when Ezetimibe is combined with Atorvastatin.Approved
FelodipineThe serum concentration of Atorvastatin can be increased when it is combined with Felodipine.Approved, Investigational
FenofibrateThe risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Atorvastatin.Approved
Fenofibric acidThe risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibric acid is combined with Atorvastatin.Approved
FentanylThe serum concentration of Atorvastatin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe risk or severity of myopathy can be increased when Fenticonazole is combined with Atorvastatin.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atorvastatin.Approved
FidaxomicinThe risk or severity of adverse effects can be increased when Fidaxomicin is combined with Atorvastatin.Approved
FluconazoleThe serum concentration of Atorvastatin can be increased when it is combined with Fluconazole.Approved, Investigational
FluoxetineThe serum concentration of Atorvastatin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlurithromycinThe risk or severity of rhabdomyolysis can be increased when Flurithromycin is combined with Atorvastatin.Experimental
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Atorvastatin.Approved
FlutrimazoleThe risk or severity of myopathy can be increased when Flutrimazole is combined with Atorvastatin.Experimental
FluvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Fluvastatin is combined with Atorvastatin.Approved
FluvoxamineThe metabolism of Atorvastatin can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe risk or severity of adverse effects can be increased when Fosamprenavir is combined with Atorvastatin.Approved
FosaprepitantThe risk or severity of adverse effects can be increased when Fosaprepitant is combined with Atorvastatin.Approved
FosnetupitantThe risk or severity of adverse effects can be increased when Fosnetupitant is combined with Atorvastatin.Approved
FosphenytoinThe serum concentration of Atorvastatin can be decreased when it is combined with Fosphenytoin.Approved, Investigational
Fusidic AcidThe serum concentration of Atorvastatin can be increased when it is combined with Fusidic Acid.Approved, Investigational
GallopamilThe serum concentration of Atorvastatin can be increased when it is combined with Gallopamil.Investigational
GanciclovirThe risk or severity of myopathy and rhabdomyolysis can be increased when Ganciclovir is combined with Atorvastatin.Approved, Investigational
GemfibrozilThe risk or severity of adverse effects can be increased when Gemfibrozil is combined with Atorvastatin.Approved
GlibornurideAtorvastatin may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideAtorvastatin may increase the hypoglycemic activities of Gliclazide.Approved
GliquidoneAtorvastatin may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideAtorvastatin may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideThe serum concentration of Atorvastatin can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Atorvastatin can be increased when it is combined with Glycerin.Approved, Investigational
Glycerol PhenylbutyrateThe risk or severity of adverse effects can be increased when Glycerol Phenylbutyrate is combined with Atorvastatin.Approved
GPI-1485The risk or severity of rhabdomyolysis can be increased when GPI-1485 is combined with Atorvastatin.Investigational
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Atorvastatin.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Atorvastatin.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Atorvastatin.Approved, Vet Approved
HydrotalciteThe serum concentration of Atorvastatin can be decreased when it is combined with Hydrotalcite.Approved, Experimental, Investigational
IbandronateThe risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Atorvastatin.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Atorvastatin.Approved
IbuprofenThe serum concentration of Atorvastatin can be increased when it is combined with Ibuprofen.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Idelalisib is combined with Atorvastatin.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Atorvastatin.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Atorvastatin.Approved
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Atorvastatin.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Imidapril.Investigational
IndinavirThe risk or severity of adverse effects can be increased when Indinavir is combined with Atorvastatin.Approved
IndisulamThe risk or severity of adverse effects can be increased when Indisulam is combined with Atorvastatin.Investigational
Insulin HumanAtorvastatin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkAtorvastatin may increase the hypoglycemic activities of Insulin Pork.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Atorvastatin.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Atorvastatin.Approved, Investigational
IsavuconazoleThe serum concentration of Atorvastatin can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe risk or severity of adverse effects can be increased when Isavuconazonium is combined with Atorvastatin.Approved, Investigational
IsoconazoleThe risk or severity of myopathy can be increased when Isoconazole is combined with Atorvastatin.Approved
IsoniazidThe risk or severity of adverse effects can be increased when Isoniazid is combined with Atorvastatin.Approved, Investigational
IsradipineThe serum concentration of Atorvastatin can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Atorvastatin.Approved, Investigational
IvacaftorThe risk or severity of adverse effects can be increased when Ivacaftor is combined with Atorvastatin.Approved
IvermectinThe risk or severity of rhabdomyolysis can be increased when Ivermectin is combined with Atorvastatin.Approved, Investigational, Vet Approved
IxabepiloneThe risk or severity of rhabdomyolysis can be increased when Ixabepilone is combined with Atorvastatin.Approved, Investigational
JosamycinThe risk or severity of adverse effects can be increased when Josamycin is combined with Atorvastatin.Approved, Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Atorvastatin.Approved
KetoconazoleThe serum concentration of Atorvastatin can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Atorvastatin.Experimental
KOS-1584The risk or severity of rhabdomyolysis can be increased when KOS-1584 is combined with Atorvastatin.Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Atorvastatin.Approved, Investigational
LamotrigineThe serum concentration of Atorvastatin can be decreased when it is combined with Lamotrigine.Approved, Investigational
LansoprazoleThe risk or severity of adverse effects can be increased when Lansoprazole is combined with Atorvastatin.Approved, Investigational
Lanthanum carbonateThe serum concentration of Atorvastatin can be decreased when it is combined with Lanthanum carbonate.Approved
LapatinibThe risk or severity of adverse effects can be increased when Lapatinib is combined with Atorvastatin.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Atorvastatin.Approved
LercanidipineThe risk or severity of myopathy and rhabdomyolysis can be increased when Lercanidipine is combined with Atorvastatin.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Atorvastatin.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Levofloxacin is combined with Atorvastatin.Approved, Investigational
LevosalbutamolThe risk or severity of adverse effects can be increased when Levosalbutamol is combined with Atorvastatin.Approved, Investigational
LidocaineThe serum concentration of Atorvastatin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Atorvastatin.Approved
LipegfilgrastimAtorvastatin may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Atorvastatin.Approved, Investigational
LomerizineThe serum concentration of Atorvastatin can be increased when it is combined with Lomerizine.Experimental
LomitapideThe risk or severity of adverse effects can be increased when Lomitapide is combined with Atorvastatin.Approved, Investigational
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with Atorvastatin.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Atorvastatin.Approved
LopinavirThe risk or severity of adverse effects can be increased when Lopinavir is combined with Atorvastatin.Approved
LoratadineThe serum concentration of Atorvastatin can be increased when it is combined with Loratadine.Approved, Investigational
LorpiprazoleThe serum concentration of Atorvastatin can be increased when it is combined with Lorpiprazole.Approved
Lorvotuzumab mertansineThe risk or severity of rhabdomyolysis can be increased when Lorvotuzumab mertansine is combined with Atorvastatin.Investigational
LosartanThe serum concentration of Losartan can be increased when it is combined with Atorvastatin.Approved
LovastatinThe risk or severity of adverse effects can be increased when Lovastatin is combined with Atorvastatin.Approved, Investigational
LuliconazoleThe risk or severity of adverse effects can be increased when Luliconazole is combined with Atorvastatin.Approved
LumacaftorThe serum concentration of Atorvastatin can be increased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Atorvastatin.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Atorvastatin.Illicit, Investigational, Withdrawn
MagaldrateThe serum concentration of Atorvastatin can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium oxideThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium silicate.Approved
ManidipineThe metabolism of Atorvastatin can be decreased when combined with Manidipine.Approved, Investigational
MefloquineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Atorvastatin.Approved, Investigational
MepartricinThe risk or severity of rhabdomyolysis can be increased when Mepartricin is combined with Atorvastatin.Experimental
MequitazineThe risk or severity of adverse effects can be increased when Mequitazine is combined with Atorvastatin.Approved
MetahexamideAtorvastatin may increase the hypoglycemic activities of Metahexamide.Experimental
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Atorvastatin.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Atorvastatin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Atorvastatin.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Atorvastatin.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Atorvastatin.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Atorvastatin.Approved
MetoclopramideThe risk or severity of myopathy and rhabdomyolysis can be increased when Metoclopramide is combined with Atorvastatin.Approved, Investigational
MetronidazoleThe risk or severity of adverse effects can be increased when Metronidazole is combined with Atorvastatin.Approved
MetyraponeThe risk or severity of adverse effects can be increased when Metyrapone is combined with Atorvastatin.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Atorvastatin.Experimental
MibefradilThe metabolism of Atorvastatin can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe risk or severity of myopathy can be increased when Miconazole is combined with Atorvastatin.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Atorvastatin.Approved, Illicit
MidecamycinThe risk or severity of rhabdomyolysis can be increased when Midecamycin is combined with Atorvastatin.Approved
MifepristoneThe risk or severity of adverse effects can be increased when Mifepristone is combined with Atorvastatin.Approved, Investigational
MiocamycinThe risk or severity of rhabdomyolysis can be increased when Miocamycin is combined with Atorvastatin.Experimental
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Atorvastatin.Approved
Mirvetuximab SoravtansineThe risk or severity of rhabdomyolysis can be increased when Mirvetuximab Soravtansine is combined with Atorvastatin.Investigational
MitemcinalThe risk or severity of rhabdomyolysis can be increased when Mitemcinal is combined with Atorvastatin.Investigational
MitotaneThe serum concentration of Atorvastatin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Atorvastatin.Approved, Investigational
ModafinilThe risk or severity of adverse effects can be increased when Modafinil is combined with Atorvastatin.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Moexipril.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Atorvastatin.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Atorvastatin.Approved
NatamycinThe risk or severity of rhabdomyolysis can be increased when Natamycin is combined with Atorvastatin.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Atorvastatin.Approved, Withdrawn
NelfinavirThe risk or severity of adverse effects can be increased when Nelfinavir is combined with Atorvastatin.Approved
NetupitantThe risk or severity of adverse effects can be increased when Netupitant is combined with Atorvastatin.Approved, Investigational
NevirapineThe risk or severity of adverse effects can be increased when Nevirapine is combined with Atorvastatin.Approved
NiacinThe risk or severity of rhabdomyolysis can be increased when Niacin is combined with Atorvastatin.Approved, Investigational, Nutraceutical
NicardipineThe metabolism of Atorvastatin can be decreased when combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Atorvastatin.Approved, Investigational
NicotinamideThe risk or severity of adverse effects can be increased when Nicotinamide is combined with Atorvastatin.Approved, Investigational
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Atorvastatin.Approved
NiguldipineThe serum concentration of Atorvastatin can be increased when it is combined with Niguldipine.Experimental
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Atorvastatin.Approved, Investigational
NimodipineThe serum concentration of Atorvastatin can be increased when it is combined with Nimodipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Atorvastatin.Approved
NisoldipineThe serum concentration of Atorvastatin can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Atorvastatin can be increased when it is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Atorvastatin.Approved
NorfloxacinThe risk or severity of adverse effects can be increased when Norfloxacin is combined with Atorvastatin.Approved
NoscapineThe risk or severity of adverse effects can be increased when Noscapine is combined with Atorvastatin.Investigational
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Atorvastatin.Approved, Vet Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Atorvastatin.Approved, Investigational
OlaparibThe risk or severity of adverse effects can be increased when Olaparib is combined with Atorvastatin.Approved
OleandomycinThe risk or severity of adverse effects can be increased when Oleandomycin is combined with Atorvastatin.Vet Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Atorvastatin can be increased when it is combined with Ombitasvir.Approved, Investigational
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Atorvastatin.Approved, Investigational, Vet Approved
OmoconazoleThe risk or severity of myopathy can be increased when Omoconazole is combined with Atorvastatin.Experimental
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Atorvastatin.Approved
OsimertinibThe serum concentration of Atorvastatin can be increased when it is combined with Osimertinib.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Oxetacaine is combined with Atorvastatin.Approved, Investigational
OxiconazoleThe risk or severity of myopathy can be increased when Oxiconazole is combined with Atorvastatin.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Atorvastatin.Approved, Investigational
OxymetholoneThe risk or severity of adverse effects can be increased when Oxymetholone is combined with Atorvastatin.Approved, Illicit
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Atorvastatin.Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Palbociclib is combined with Atorvastatin.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Atorvastatin.Approved
ParitaprevirThe serum concentration of Atorvastatin can be increased when it is combined with Paritaprevir.Approved, Investigational
ParoxetineThe serum concentration of Atorvastatin can be increased when it is combined with Paroxetine.Approved, Investigational
PatupiloneThe risk or severity of rhabdomyolysis can be increased when Patupilone is combined with Atorvastatin.Experimental, Investigational
PazopanibThe risk or severity of adverse effects can be increased when Pazopanib is combined with Atorvastatin.Approved
PentobarbitalThe metabolism of Atorvastatin can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Peppermint oilThe risk or severity of adverse effects can be increased when Peppermint oil is combined with Atorvastatin.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Atorvastatin.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Perindopril.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Atorvastatin.Approved
PhenobarbitalThe serum concentration of Atorvastatin can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenytoinThe serum concentration of Atorvastatin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe risk or severity of adverse effects can be increased when Pilocarpine is combined with Atorvastatin.Approved, Investigational
PimecrolimusThe risk or severity of rhabdomyolysis can be increased when Pimecrolimus is combined with Atorvastatin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Atorvastatin.Approved
PioglitazoneThe metabolism of Atorvastatin can be decreased when combined with Pioglitazone.Approved, Investigational
PiperaquineThe risk or severity of adverse effects can be increased when Piperaquine is combined with Atorvastatin.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Atorvastatin.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Atorvastatin.Approved, Investigational
PosaconazoleThe serum concentration of Atorvastatin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe risk or severity of adverse effects can be increased when Pravastatin is combined with Atorvastatin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Atorvastatin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Atorvastatin.Approved, Vet Approved
PrimaquineThe risk or severity of adverse effects can be increased when Primaquine is combined with Atorvastatin.Approved
PrimidoneThe metabolism of Atorvastatin can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe risk or severity of adverse effects can be increased when Progesterone is combined with Atorvastatin.Approved, Vet Approved
PromethazineThe serum concentration of Atorvastatin can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Atorvastatin can be increased when it is combined with Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Atorvastatin.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Atorvastatin.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Atorvastatin.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Atorvastatin.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Quinapril.Approved, Investigational
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Atorvastatin.Approved, Investigational
QuinineThe risk or severity of renal failure and rhabdomyolysis can be increased when Quinine is combined with Atorvastatin.Approved
QuinupristinThe risk or severity of adverse effects can be increased when Quinupristin is combined with Atorvastatin.Approved
RabeprazoleThe risk or severity of adverse effects can be increased when Rabeprazole is combined with Atorvastatin.Approved, Investigational
RaloxifeneThe risk or severity of adverse effects can be increased when Raloxifene is combined with Atorvastatin.Approved, Investigational
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Atorvastatin.Approved
RamiprilThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Ramipril.Approved
RanitidineThe serum concentration of Atorvastatin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Atorvastatin can be increased when it is combined with Ranolazine.Approved, Investigational
RavuconazoleThe risk or severity of myopathy can be increased when Ravuconazole is combined with Atorvastatin.Investigational
RegorafenibThe risk or severity of adverse effects can be increased when Regorafenib is combined with Atorvastatin.Approved
RepaglinideThe risk or severity of adverse effects can be increased when Repaglinide is combined with Atorvastatin.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Atorvastatin.Approved, Experimental, Investigational
RibociclibThe serum concentration of Atorvastatin can be increased when it is combined with Ribociclib.Approved, Investigational
RidaforolimusThe risk or severity of rhabdomyolysis can be increased when Ridaforolimus is combined with Atorvastatin.Investigational
RifabutinThe metabolism of Atorvastatin can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Atorvastatin can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Atorvastatin can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Atorvastatin.Approved, Investigational
RilpivirineThe serum concentration of Atorvastatin can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Atorvastatin.Approved, Investigational
RitonavirThe serum concentration of Atorvastatin can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Rivastigmine is combined with Atorvastatin.Approved, Investigational
RokitamycinThe risk or severity of rhabdomyolysis can be increased when Rokitamycin is combined with Atorvastatin.Experimental
RolitetracyclineThe risk or severity of adverse effects can be increased when Rolitetracycline is combined with Atorvastatin.Approved
RosiglitazoneThe excretion of Atorvastatin can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Atorvastatin is combined with Rosuvastatin.Approved
RoxithromycinThe risk or severity of adverse effects can be increased when Roxithromycin is combined with Atorvastatin.Approved, Investigational, Withdrawn
RucaparibThe risk or severity of adverse effects can be increased when Rucaparib is combined with Atorvastatin.Approved, Investigational
RutinThe risk or severity of adverse effects can be increased when Rutin is combined with Atorvastatin.Experimental, Investigational
SagopiloneThe risk or severity of rhabdomyolysis can be increased when Sagopilone is combined with Atorvastatin.Investigational
SalmeterolThe risk or severity of myopathy and rhabdomyolysis can be increased when Salmeterol is combined with Atorvastatin.Approved
SaquinavirThe risk or severity of adverse effects can be increased when Saquinavir is combined with Atorvastatin.Approved, Investigational
SarilumabThe risk or severity of adverse effects can be increased when Sarilumab is combined with Atorvastatin.Approved, Investigational
SecobarbitalThe metabolism of Atorvastatin can be increased when combined with Secobarbital.Approved, Vet Approved
SelamectinThe risk or severity of rhabdomyolysis can be increased when Selamectin is combined with Atorvastatin.Vet Approved
SertaconazoleThe risk or severity of myopathy can be increased when Sertaconazole is combined with Atorvastatin.Approved, Investigational
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Atorvastatin.Approved
SildenafilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Atorvastatin.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Atorvastatin.Approved
SiltuximabThe serum concentration of Atorvastatin can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Atorvastatin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Simvastatin is combined with Atorvastatin.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Atorvastatin.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Atorvastatin.Approved, Investigational
SitaxentanThe risk or severity of adverse effects can be increased when Sitaxentan is combined with Atorvastatin.Approved, Investigational, Withdrawn
Sodium bicarbonateThe serum concentration of Atorvastatin can be decreased when it is combined with Sodium bicarbonate.Approved
SolithromycinThe risk or severity of adverse effects can be increased when Solithromycin is combined with Atorvastatin.Investigational
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Atorvastatin.Approved, Investigational
SpiramycinThe risk or severity of adverse effects can be increased when Spiramycin is combined with Atorvastatin.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Spirapril.Approved
St. John's WortThe metabolism of Atorvastatin can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Atorvastatin.Approved
SulconazoleThe risk or severity of myopathy can be increased when Sulconazole is combined with Atorvastatin.Approved
SulfamethoxazoleThe risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Atorvastatin.Approved
SulfanilamideThe risk or severity of adverse effects can be increased when Sulfanilamide is combined with Atorvastatin.Approved
SulfasalazineThe excretion of Atorvastatin can be decreased when combined with Sulfasalazine.Approved
SulfinpyrazoneThe risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Atorvastatin.Approved
SulfisoxazoleThe risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Atorvastatin.Approved, Vet Approved
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Atorvastatin.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Atorvastatin.Approved, Investigational
TadalafilThe risk or severity of adverse effects can be increased when Tadalafil is combined with Atorvastatin.Approved, Investigational
TamoxifenThe risk or severity of adverse effects can be increased when Tamoxifen is combined with Atorvastatin.Approved
TelaprevirThe serum concentration of Atorvastatin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe risk or severity of adverse effects can be increased when Telithromycin is combined with Atorvastatin.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Atorvastatin.Approved
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Atorvastatin.Approved
TerbinafineThe risk or severity of myopathy and rhabdomyolysis can be increased when Terbinafine is combined with Atorvastatin.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of myopathy can be increased when Terconazole is combined with Atorvastatin.Approved
TerfenadineThe risk or severity of adverse effects can be increased when Terfenadine is combined with Atorvastatin.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Atorvastatin.Experimental
TeriflunomideThe serum concentration of Atorvastatin can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Atorvastatin.Investigational
TestosteroneThe risk or severity of adverse effects can be increased when Testosterone is combined with Atorvastatin.Approved, Investigational
Testosterone cypionateThe risk or severity of adverse effects can be increased when Testosterone cypionate is combined with Atorvastatin.Approved
Testosterone enanthateThe risk or severity of adverse effects can be increased when Testosterone enanthate is combined with Atorvastatin.Approved
Testosterone undecanoateThe risk or severity of adverse effects can be increased when Testosterone undecanoate is combined with Atorvastatin.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Atorvastatin.Approved, Vet Approved
TetrandrineThe serum concentration of Atorvastatin can be increased when it is combined with Tetrandrine.Experimental
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Atorvastatin.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Atorvastatin.Approved, Withdrawn
TicagrelorThe serum concentration of Atorvastatin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Atorvastatin.Approved
TildipirosinThe risk or severity of rhabdomyolysis can be increased when Tildipirosin is combined with Atorvastatin.Vet Approved
TilmicosinThe risk or severity of rhabdomyolysis can be increased when Tilmicosin is combined with Atorvastatin.Investigational, Vet Approved
TioconazoleThe risk or severity of myopathy can be increased when Tioconazole is combined with Atorvastatin.Approved
TipranavirThe serum concentration of Atorvastatin can be increased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Atorvastatin can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Tofisopam is combined with Atorvastatin.Approved
TolazamideAtorvastatin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideAtorvastatin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Atorvastatin.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Atorvastatin.Approved
TopiroxostatThe risk or severity of adverse effects can be increased when Topiroxostat is combined with Atorvastatin.Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Topotecan is combined with Atorvastatin.Approved, Investigational
TrabectedinAtorvastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Atorvastatin.Approved, Investigational
Trastuzumab emtansineThe risk or severity of rhabdomyolysis can be increased when Trastuzumab emtansine is combined with Atorvastatin.Approved, Investigational
TrimethoprimThe metabolism of Atorvastatin can be decreased when combined with Trimethoprim.Approved, Vet Approved
TroglitazoneThe risk or severity of adverse effects can be increased when Troglitazone is combined with Atorvastatin.Investigational, Withdrawn
TroleandomycinThe risk or severity of adverse effects can be increased when Troleandomycin is combined with Atorvastatin.Approved
TromethamineThe serum concentration of Atorvastatin can be decreased when it is combined with Tromethamine.Approved
TylosinThe risk or severity of adverse effects can be increased when Tylosin is combined with Atorvastatin.Vet Approved
TylvalosinThe risk or severity of rhabdomyolysis can be increased when Tylvalosin is combined with Atorvastatin.Vet Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Atorvastatin.Approved
VemurafenibThe serum concentration of Atorvastatin can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Atorvastatin.Approved
VerapamilAtorvastatin can cause a decrease in the absorption of Verapamil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Atorvastatin.Approved
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with Atorvastatin.Approved, Investigational
VincristineThe excretion of Vincristine can be decreased when combined with Atorvastatin.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Atorvastatin.Approved, Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Atorvastatin.Approved, Investigational
ZafirlukastThe risk or severity of adverse effects can be increased when Zafirlukast is combined with Atorvastatin.Approved, Investigational
ZidovudineThe serum concentration of Atorvastatin can be decreased when it is combined with Zidovudine.Approved
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Atorvastatin.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Zofenopril.Experimental
ZucapsaicinThe risk or severity of adverse effects can be increased when Zucapsaicin is combined with Atorvastatin.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid drastic changes in dietary habit.
  • Avoid taking grapefruit or grapefruit juice throughout treatment. Grapefruit can significantly increase serum levels of this product.
  • Food may decrease maximum plasma levels and area under the curve, but this is clinically inconsequential according to the manufacturer.
  • Take with low fat meal.

References

Synthesis Reference

Zlatko Pflaum, "Process for the preparation of amorphous atorvastatin." U.S. Patent US20020183527, issued December 05, 2002.

US20020183527
General References
  1. Rouleau J: Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial. Am J Med. 2005 Dec;118 Suppl 12A:28-35. [PubMed:16356805]
  2. Maggon K: Best-selling human medicines 2002-2004. Drug Discov Today. 2005 Jun 1;10(11):739-42. [PubMed:15922927]
External Links
Human Metabolome Database
HMDB0005006
KEGG Drug
D07474
KEGG Compound
C06834
PubChem Compound
60823
PubChem Substance
46506188
ChemSpider
54810
BindingDB
22164
ChEBI
39548
ChEMBL
CHEMBL1487
Therapeutic Targets Database
DAP000553
PharmGKB
PA448500
HET
117
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Atorvastatin
ATC Codes
C10AA05 — AtorvastatinC10BA05 — Atorvastatin and ezetimibeC10BX06 — Atorvastatin, acetylsalicylic acid and ramiprilC10BX11 — Atorvastatin, amlodipine and perindoprilC10BX03 — Atorvastatin and amlodipineC10BX08 — Atorvastatin and acetylsalicylic acid
AHFS Codes
  • 24:06.08 — Hmg-coa Reductase Inhibitors
PDB Entries
1hwk
FDA label
Download (62 KB)
MSDS
Download (57.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingBasic ScienceObstructive Sleep Apnea of Adult1
0RecruitingTreatmentCancer of the Breast / Cancer, Breast / Tumors, Breast1
0RecruitingTreatmentEndometrial Cancers1
0Unknown StatusPreventionStroke, Ischemic / Ventilator-Associated Pneumonia (VAP)1
1Active Not RecruitingTreatmentHealthy Male Subjects1
1CompletedNot AvailableAcute Coronary Syndromes (ACS)1
1CompletedNot AvailableEffect of Atorvastatin on the Pharmacokinetics of Lomitapide1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Atorvastatin1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Atorvastatin / Pharmacokinetics of Isavuconazole1
1CompletedNot AvailableHigh Blood Cholesterol Level3
1CompletedNot AvailableHigh Blood Cholesterol Level / Human Immunodeficiency Virus (HIV)1
1CompletedNot AvailableHigh Blood Pressure (Hypertension)1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1CompletedNot AvailableHypertension,Essential1
1CompletedNot AvailablePediatric Heterozygous Hypercholesterolemia1
1CompletedBasic ScienceCoronary Heart Disease (CHD)1
1CompletedBasic ScienceDiabetes Mellitus (DM) / Healthy Volunteers1
1CompletedBasic ScienceDyslipidemias1
1CompletedBasic ScienceHealthy Volunteers3
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics1
1CompletedBasic ScienceHigh Blood Cholesterol Level1
1CompletedDiagnosticBone destruction / Osteoarthritis (OA)1
1CompletedHealth Services ResearchHealthy Controls1
1CompletedOtherHealthy Volunteers1
1CompletedPreventionAtypical Ductal Breast Hyperplasia / Cancer, Breast / Ductal Breast Carcinoma In Situ / Lobular Breast Carcinoma In Situ1
1CompletedTreatmentAcute Coronary Syndromes (ACS) / Inflammatory Reaction / Myocardial Infarction / Reperfusion Injury1
1CompletedTreatmentAcute and Chronic Inflammation / Autoimmune Diseases / Disorder of Pleura and Pleural Cavity / Disorder of Synovium / Felty's Syndrome / Rheumatoid Arthritis / Rheumatoid Nodules / Sjögren's Syndrome1
1CompletedTreatmentAtherosclerotic Vascular Diseases1
1CompletedTreatmentAutoimmune Diseases / Disseminated or Multiple Sclerosis Nos / Disseminated Sclerosis / Multiple Sclerosis, Acute Relapsing / Multiple Sclerosis, Chronic Progressive / Multiple Sclerosis, Primary Progressive1
1CompletedTreatmentCholesterol, LDL / High Blood Cholesterol Level1
1CompletedTreatmentDiabetes Mellitus (DM) / Healthy Volunteers1
1CompletedTreatmentDiseases of the Circulatory System / Hypertension,Essential1
1CompletedTreatmentDyslipidemia (Fredrickson Type Ⅱa) / Dyslipidemia (Fredrickson Type Ⅱb)1
1CompletedTreatmentDyslipidemias1
1CompletedTreatmentEnd-Stage Kidney Disease1
1CompletedTreatmentEndometriosis / Prostate Cancer1
1CompletedTreatmentEpilepsies1
1CompletedTreatmentHIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
1CompletedTreatmentHealthy Participants1
1CompletedTreatmentHealthy Volunteers18
1CompletedTreatmentHealthy Volunteers / Normocholesterolaemic Men / Normozoospermic Men1
1CompletedTreatmentHigh Blood Pressure (Hypertension) / Hyperlipidemias2
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHyperlipidemias1
1CompletedTreatmentHyperlipidemias / Hypertension,Essential2
1CompletedTreatmentHypertension With Hyperlipidemia / Hypertention With Hyperlipidemia1
1CompletedTreatmentHypertension, Hyperlipidemia1
1CompletedTreatmentImpaired Renal Function1
1CompletedTreatmentPharmacokinetics1
1CompletedTreatmentSleep disorders and disturbances1
1Not Yet RecruitingNot AvailableHealthy Male Subjects1
1RecruitingTreatmentDyslipidemias1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Malignant Diseases / Tumors, Solid1
1TerminatedDiagnosticPeripheral Arterial Disease (PAD)1
1TerminatedTreatmentDiabetes, Diabetes Mellitus Type 11
1Unknown StatusTreatmentHealthy Volunteers1
1Unknown StatusTreatmentPlasma Cell Myeloma1
1Unknown StatusTreatmentStrokes1
1WithdrawnBasic ScienceAdvanced Adenocarcinoma of the Colon or Rectum1
1, 2CompletedTreatmentMetabolic Syndromes1
1, 2CompletedTreatmentMucocutaneous Lymph Node Syndrome1
1, 2CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
1, 2Enrolling by InvitationBasic ScienceSleep Apnea, Obstructive1
1, 2Not Yet RecruitingTreatmentCerebral Cavernous Malformations1
1, 2Not Yet RecruitingTreatmentEbola Virus Disease1
1, 2Not Yet RecruitingTreatmentImmune Thrombocytopenia1
1, 2RecruitingPreventionPrimary Arteriovenous Fistula Failure1
1, 2RecruitingTreatmentNon-segmental Vitiligo1
1, 2RecruitingTreatmentVenous Thromboembolism (VTE)1
1, 2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Hyperlipidemias1
1, 2Unknown StatusTreatmentMetabolic Syndromes1
1, 2Unknown StatusTreatmentStenosis1
2Active Not RecruitingPreventionCancer, Breast1
2Active Not RecruitingPreventionGraft Versus Host Disease (GVHD)1
2Active Not RecruitingPreventionHigh Blood Pressure (Hypertension) / Hyperlipidemias1
2Active Not RecruitingTreatmentSpastic Paraplegia, Hereditary1
2CompletedBasic ScienceHuman Immunodeficiency Virus (HIV)1
2CompletedDiagnosticHealthy Volunteers1
2CompletedPreventionAlzheimer's Disease (AD)1
2CompletedPreventionDisseminated Sclerosis1
2CompletedPreventionHip Fractures / Inflammatory Reaction / Myocardial Ischemia1
2CompletedPreventionMalignant Neoplasm of Colon / Precancerous Conditions / Rectal Carcinoma1
2CompletedPreventionMetabolic Syndromes1
2CompletedPreventionProstatic Neoplasms1
2CompletedSupportive CareAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome1
2CompletedSupportive CareNeoplasms, Malignant1
2CompletedTreatmentALL, Childhood / Cardiovascular Disease (CVD) / Childhood NHL1
2CompletedTreatmentAcute Coronary Syndromes (ACS)1
2CompletedTreatmentAlzheimer's Disease (AD)1
2CompletedTreatmentAngioplasty, Transluminal, Percutaneous Coronary / Myocardial Infarction / Transplantation, Stem Cell1
2CompletedTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD) / Smoking1
2CompletedTreatmentCancer, Breast / One to five years postmenopausal1
2CompletedTreatmentCardiovascular Disease (CVD)1
2CompletedTreatmentCardiovascular Disease (CVD) / Diabetes Mellitus (DM) / Renal Dysfunction1
2CompletedTreatmentCardiovascular Disease (CVD) / Renal Dysfunction2
2CompletedTreatmentCarotid Atherosclerosis1
2CompletedTreatmentChronic Subdural Hematomas1
2CompletedTreatmentCrohns Disease1
2CompletedTreatmentDiabetes Mellitus (DM)1
2CompletedTreatmentDiabetes Mellitus (DM) / High Blood Cholesterol Level / Metabolic Syndromes1
2CompletedTreatmentDiabetes Mellitus (DM) / Ulcus Cruris1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentDisseminated Sclerosis1
2CompletedTreatmentDyslipidemias8
2CompletedTreatmentGlioblastoma Multiforme (GBM)1
2CompletedTreatmentGlomerulosclerosis, Focal Segmental1
2CompletedTreatmentHepatitis C Viral Infection1
2CompletedTreatmentHigh Blood Cholesterol Level12
2CompletedTreatmentHigh Blood Cholesterol Level / Hyperlipidemias / Muscle Soreness1
2CompletedTreatmentHyperlipidemias5
2CompletedTreatmentInfection, Human Immunodeficiency Virus I1
2CompletedTreatmentKnee Osteoarthritis (Knee OA)1
2CompletedTreatmentLeukemias / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentNonalcoholic Steatohepatitis1
2CompletedTreatmentPlatelets Dysfunction1
2CompletedTreatmentPolycystic Ovaries Syndrome1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentPsoriasis1
2CompletedTreatmentPulmonary Hypertension (PH)1
2CompletedTreatmentRenal Cancers / Renal Cell Adenocarcinoma1
2CompletedTreatmentRheumatoid Arthritis1
2CompletedTreatmentSarcoidosis, Pulmonary1
2CompletedTreatmentSickle Cell Disorders / Sickle Cell Nephropathy1
2CompletedTreatmentVascular Diseases1
2CompletedTreatmentVitiligo1
2Not Yet RecruitingPreventionCancers / Cardiotoxicity / Heart Failure, Unspecified1
2Not Yet RecruitingTreatmentAngioplasty, Transluminal, Percutaneous Coronary / Myocardial Infarction / Transplantation, Stem Cell1
2Not Yet RecruitingTreatmentChronic Subdural Hematomas1
2Not Yet RecruitingTreatmentDyslipidemias1
2Not Yet RecruitingTreatmentDyslipidemias / High Blood Cholesterol Level1
2Not Yet RecruitingTreatmentHigh Blood Cholesterol Level / Thyroid Associated Ophthalmopathy1
2Not Yet RecruitingTreatmentNeoplasms, Breast1
2Not Yet RecruitingTreatmentProstate Cancer1
2Not Yet RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
2RecruitingPreventionAdult Acute Lymphoblastic Leukemia / Adult Acute Myeloid Leukemia / Adult Diffuse Large B-Cell Lymphoma / Aggressive Non-Hodgkin Lymphoma / Aggressive, recurrent Adult Non-Hodgkin Lymphoma / Blasts Under 5 Percent of Bone Marrow Nucleated Cells / Childhood Acute Lymphoblastic Leukemia / Childhood Acute Myeloid Leukemia / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Diffuse Large B -Cell Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic, recurrent Lymphocytic Leukemia / DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Leukemia, Prolymphocytic / Loss of Chromosome 17p / Myelodysplastic/Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Non-Hodgkin Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Stage I Adult Hodgkin Lymphoma / Stage I Aggressive Adult Non-Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Diffuse Large B-Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Contiguous Adult Aggressive Non-Hodgkin Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Non-Contiguous Aggressive Adult Non-Hodgkin Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage II Small Lymphocytic Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Aggressive Adult Non-Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Diffuse Large B-Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Aggressive Adult Non-Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Small Lymphocytic Lymphoma / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia / Waldenström's Macroglobulinemia (WM)1
2RecruitingPreventionCoronary Artery Disease1
2RecruitingPreventionHigh Blood Cholesterol Level1
2RecruitingTreatmentBipolar Disorder (BD) / Lithium Use, Nephrogenic Diabetes Insipidus1
2RecruitingTreatmentCancer, Breast1
2RecruitingTreatmentClinical Outcome Improvement1
2RecruitingTreatmentFlu caused by Influenza1
2RecruitingTreatmentHeart Failure, Unspecified1
2RecruitingTreatmentHigh Blood Pressure (Hypertension)1
2RecruitingTreatmentNon-Alcoholic Steatohepatitis1
2RecruitingTreatmentScleroderma1
2SuspendedPreventionNasopharyngeal Carcinoma / Radiation Therapy Complication1
2TerminatedBasic ScienceCoronary Artery Disease / Dyslipidemias1
2TerminatedPreventionAvascular Necrosis1
2TerminatedTreatmentAsthma Bronchial1
2TerminatedTreatmentCancer, Breast / Cardiotoxicity / Heart Diseases / Myocardial Dysfunction1
2TerminatedTreatmentGlomerulonephritis minimal lesion / Hyperlipidemias1
2TerminatedTreatmentHigh Blood Cholesterol Level / Venous Thromboembolism (VTE)1
2TerminatedTreatmentMild Traumatic Brain Injury (MTBI) / Post-Traumatic Stress Disorder (PTSD) / Traumatic Brain Injury (TBI)1
2TerminatedTreatmentObstructive Sleep Apnea Syndrome (OSAS)1
2Unknown StatusPreventionAcute Non-ST-segment Elevation Myocardial Infarction / Stable Angina (SA) / Unstable Angina (UA)1
2Unknown StatusPreventionCancer, Breast1
2Unknown StatusPreventionGraft Versus Host Disease (GVHD)1
2Unknown StatusPreventionProstatic Neoplasms1
2Unknown StatusTreatmentAneurysm, Coronary / Mucocutaneous Lymph Node Syndrome1
2Unknown StatusTreatmentSepsis1
2, 3CompletedPreventionMyocardial Infarction / Renal Failure / Strokes1
2, 3CompletedPreventionProphylaxis of Contrast-induced nephropathy1
2, 3CompletedTreatmentAcute Kidney Dysfunction1
2, 3CompletedTreatmentArterial Occlusive Diseases / Insulin Resistance / Intermittent Claudication1
2, 3CompletedTreatmentAsthma Bronchial1
2, 3CompletedTreatmentDyslipidemias1
2, 3CompletedTreatmentPeriodontitis, Chronic4
2, 3RecruitingPreventionCognitively Normal Older Adults / Family History of Alzheimer's Disease / High Blood Pressure (Hypertension) / Subjective Cognitive Decline1
2, 3RecruitingTreatmentHyperlipidemias1
2, 3TerminatedTreatmentAdvanced Cancers1
2, 3Unknown StatusTreatmentSystemic Lupus Erythematosus (SLE)1
2, 3WithdrawnTreatmentHuman Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) / Immune Reconstitution Inflammatory Syndrome / Immune Reconstitution Syndrome / Tuberculosis1
3Active Not RecruitingTreatmentBicuspid Aortic Valve (BAV)1
3Active Not RecruitingTreatmentCoronary Artery Disease1
3Active Not RecruitingTreatmentDyslipidemia (Fredrickson Type Ⅱa)1
3Active Not RecruitingTreatmentHigh Blood Cholesterol Level1
3Active Not RecruitingTreatmentHypercholesterolemia in Coronaory Heart Disease1
3Active Not RecruitingTreatmentImpaired Renal Function1
3CompletedPreventionAcute Coronary Syndromes (ACS)1
3CompletedPreventionAortic Aneurism / Myocardial Infarction / Peripheral Vascular Disease (PVD)1
3CompletedPreventionCoronary Artery Disease1
3CompletedPreventionDiabetes, Diabetes Mellitus Type 11
3CompletedPreventionHeart Valve Diseases1
3CompletedPreventionProphylaxis of preeclampsia1
3CompletedTreatmentAcute Coronary Syndromes (ACS)2
3CompletedTreatmentAlzheimer's Disease (AD)1
3CompletedTreatmentAssess the Periprocedural Myocardial Necrosis1
3CompletedTreatmentAtherosclerosis3
3CompletedTreatmentAtherosclerosis / Calcifications, Vascular / Dyslipidemias / Inflammatory Reaction1
3CompletedTreatmentAtherosclerosis / Cardiovascular Disease (CVD)1
3CompletedTreatmentAtherosclerosis / Coronary Artery Disease / High Blood Cholesterol Level1
3CompletedTreatmentAtherosclerotic Disease / Coronary Heart Disease (CHD) / High Blood Cholesterol Level1
3CompletedTreatmentBMI >30 kg/m2 / Dyslipidemias1
3CompletedTreatmentBMI >30 kg/m2 / Dyslipidemias / Insulin Resistance1
3CompletedTreatmentCardiovascular Disorder / Diabetes Mellitus (DM)1
3CompletedTreatmentChronic Kidney Disease (CKD)1
3CompletedTreatmentCombined (Atherogenic) Dyslipidemia / Coronary Heart Disease (CHD) / Dyslipidemias / Mixed hypercholesterolemia1
3CompletedTreatmentCoronary Arteriosclerosis / Coronary Heart Disease (CHD) / Hyperlipidemias1
3CompletedTreatmentCoronary Artery Atherosclerosis1
3CompletedTreatmentCoronary Heart Disease (CHD) / Dyslipidemias / Mixed hypercholesterolemia2
3CompletedTreatmentCoronary Heart Disease (CHD) / High Blood Cholesterol Level1
3CompletedTreatmentDiabetes Mellitus, Insulin-Dependent / High Blood Cholesterol Level1
3CompletedTreatmentDiabetes, Hyperlipidemia, Mixed Dyslipidemia1
3CompletedTreatmentDyslipidemia (Fredrickson Type Ⅱa)2
3CompletedTreatmentDyslipidemia (Fredrickson Type Ⅱa) / Dyslipidemias1
3CompletedTreatmentDyslipidemia (Fredrickson Type Ⅱa) / Hyperlipidemias2
3CompletedTreatmentDyslipidemia (Fredrickson Type Ⅱa) / Mixed hypercholesterolemia1
3CompletedTreatmentDyslipidemias1
3CompletedTreatmentDyslipidemias / High Blood Cholesterol Level3
3CompletedTreatmentDyslipidemias / High Blood Cholesterol Level / Hyperlipidemias1
3CompletedTreatmentDyslipidemias / High Blood Pressure (Hypertension)1
3CompletedTreatmentDyslipidemias / Type 2 Diabetes Mellitus2
3CompletedTreatmentHeterozygous Familial Hypercholesterolemia1
3CompletedTreatmentHigh Blood Cholesterol Level27
3CompletedTreatmentHigh Blood Cholesterol Level / Metabolic Syndromes1
3CompletedTreatmentHigh Blood Cholesterol Level / Primary Biliary Cirrhosis (PBC)1
3CompletedTreatmentHigh Blood Cholesterol Level / Type 2 Diabetes Mellitus1
3CompletedTreatmentHyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events1
3CompletedTreatmentHyperlipidemias10
3CompletedTreatmentHyperlipidemias / Hypertension,Essential1
3CompletedTreatmentHyperlipidemias / Mixed hypercholesterolemia1
3CompletedTreatmentHyperlipoproteinemia Type iv / Hypertriglyceridemias1
3CompletedTreatmentHypertriglyceridemias1
3CompletedTreatmentHypertrophic Cardiomyopathy1
3CompletedTreatmentImpaired Renal Function1
3CompletedTreatmentLupus Erythematosus, Systemic1
3CompletedTreatmentMetabolic Syndromes1
3CompletedTreatmentPrimary Hyperlipidemia and Mixed Dyslipidemia1
3CompletedTreatmentType 2 Diabetes Mellitus2
3CompletedTreatmentMixed hypercholesterolemia2
3Not Yet RecruitingPreventionMyocardial Oedema1
3Not Yet RecruitingTreatmentHigh Blood Cholesterol Level1
3Not Yet RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3RecruitingPreventionAcute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
3RecruitingPreventionCardiovascular Disease (CVD) / Coronary Artery Disease / Type 2 Diabetes Mellitus1
3RecruitingPreventionCarotid Artery Stenosis / Strokes1
3RecruitingTreatmentAortic Valve Stenosis / Ventricular Hypertrophy1
3RecruitingTreatmentAtherosclerosis / Dyslipidemias1
3RecruitingTreatmentCancers / Overall Survival / Quality of Life1
3RecruitingTreatmentCombined Dyslipidemia1
3RecruitingTreatmentDyslipidemias / Type 2 Diabetes Mellitus1
3RecruitingTreatmentEssential Hypertension, Dyslipidemia1
3RecruitingTreatmentHigh Blood Cholesterol Level2
3TerminatedPreventionInflammatory Reaction / Nonvalvular Atrial Fibrillation1
3TerminatedTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease1
3TerminatedTreatmentCardiovascular Disease (CVD)1
3TerminatedTreatmentCoronary Artery Disease / High Blood Cholesterol Level1
3TerminatedTreatmentCoronary Heart Disease (CHD) / Diabetes Mellitus (DM)1
3TerminatedTreatmentDyslipidemias / High Blood Cholesterol Level / Hyperlipidemias1
3TerminatedTreatmentDyslipidemias / Hyperlipidemias1
3TerminatedTreatmentHigh Blood Cholesterol Level5
3TerminatedTreatmentHyperlipidemias1
3TerminatedTreatmentHyperlipoproteinemia Type III1
3TerminatedTreatmentStable Coronary Artery Disease Undergoing PCI1
3TerminatedTreatmentType 2 Diabetes Mellitus1
3TerminatedTreatmentMixed hypercholesterolemia1
3Unknown StatusPreventionContrast Induced Nephropathy (CIN)1
3Unknown StatusTreatmentAbdominal Surgeries1
3Unknown StatusTreatmentBranch Retinal Vein Occlusion / Central Retinal Vein Occlusion (CRVO) / Retinal Vein Occlusions(RVO) / Retinal Vein Thrombosis / Thrombosis1
3Unknown StatusTreatmentCoronary Angioplasty / Coronary Artery Disease1
3Unknown StatusTreatmentHyperlipidemia, Familial Combined1
3Unknown StatusTreatmentHyperlipidemias1
3Unknown StatusTreatmentST Elevation Myocardial Infarction (STEMI)1
3Unknown StatusTreatmentStable Coronary Artery Disease1
3Unknown StatusTreatmentMixed hypercholesterolemia1
3WithdrawnTreatmentHypertriglyceridemias1
3WithdrawnTreatmentPsoriasis1
4Active Not RecruitingBasic ScienceDrug intolerance1
4Active Not RecruitingOtherAtherosclerosis / Carotid Artery Diseases / Coronary Artery Disease1
4Active Not RecruitingTreatmentAcute Coronary Syndromes (ACS)1
4Active Not RecruitingTreatmentAcute Coronary Syndromes (ACS) / High Blood Cholesterol Level1
4Active Not RecruitingTreatmentChronic Kidney Disease (CKD)1
4Active Not RecruitingTreatmentDyslipidemias1
4Active Not RecruitingTreatmentHigh Blood Cholesterol Level / Type 2 Diabetes Mellitus1
4CompletedNot AvailableAbdominal Aortic Aneurysms (AAA)1
4CompletedNot AvailableCardiovascular Disease (CVD) / Cholesterol, LDL / Cognition / Type 2 Diabetes Mellitus1
4CompletedNot AvailableDyslipidemias / Vascular Diseases1
4CompletedNot AvailableHealthy Volunteers3
4CompletedNot AvailableHigh Blood Cholesterol Level4
4CompletedNot AvailablePrediabetic State1
4CompletedBasic ScienceAtherosclerosis / Coronary Artery Disease / Endothelial Dysfunction / HMG-CoA Reductase Inhibitor Toxicity / Oxidative Stress1
4CompletedBasic ScienceBone destruction / High Blood Cholesterol Level1
4CompletedBasic ScienceHyperlipidemias / Metabolic Syndromes / Renal Failure Chronic Requiring Hemodialysis / Type 2 Diabetes Mellitus1
4CompletedBasic SciencePeripheral Arterial Disease (PAD)1
4CompletedDiagnosticMuscular Diseases1
4CompletedDiagnosticMyopathies1
4CompletedDiagnosticMyotoxicity of Atorvastatin Treatment1
4CompletedPreventionAcute Coronary Syndromes (ACS)2
4CompletedPreventionAcute Kidney Injury (AKI) / Aortic Surgery1
4CompletedPreventionAging / Alzheimer's Disease (AD)1
4CompletedPreventionCardiac Insufficiency Following Cardiac Surgery / Disorder; Heart, Functional, Postoperative, Cardiac Surgery / Ischaemia-reperfusion Injury / Nonvalvular Atrial Fibrillation1
4CompletedPreventionCardiovascular Disease (CVD) / Cerebrovascular Accidents / Coronary Heart Disease (CHD)1
4CompletedPreventionCerebrovascular Accidents / Coronary Artery Bypass Graft / Major Coronary Event / Revascularization / Unstable Angina (UA)1
4CompletedPreventionContrast Induced Nephropathy (CIN)1
4CompletedPreventionCoronary Artery Bypass Grafting (CABG) Surgery1
4CompletedPreventionEndothelial Dysfunction / Ischemia Reperfusion Injury1
4CompletedPreventionHemostasis / Inflammatory Reaction / Magnetic Resonance Imaging (MRI) / Neuropsychology / Nonvalvular Atrial Fibrillation1
4CompletedPreventionMyocardial Infarction1
4CompletedPreventionSystemic Lupus Erythematosus (SLE)1
4CompletedPreventionType 2 Diabetes Mellitus1
4CompletedScreeningInflammatory Reaction1
4CompletedTreatmentAcute Coronary Syndromes (ACS) / Dyslipidemias1
4CompletedTreatmentAcute Ischemic Stroke (AIS)1
4CompletedTreatmentAcute Myocardial Infarction (AMI)2
4CompletedTreatmentAging-related Inflammation in HIV-infected Patients1
4CompletedTreatmentAngina Pectoris / High Blood Cholesterol Level / High Blood Pressure (Hypertension)1
4CompletedTreatmentAnginal Pain1
4CompletedTreatmentAngioplasty / Myocardial Infarction / Percutaneous Coronary1
4CompletedTreatmentArrythmias1
4CompletedTreatmentArrythmias / Endothelial Dysfunction / Inflammatory Reaction / Nonvalvular Atrial Fibrillation1
4CompletedTreatmentArteriosclerosis / Calcinosis / Hyperparathyroidism, Secondary1
4CompletedTreatmentAtherosclerosis1
4CompletedTreatmentAtherosclerosis / Coronary Artery Disease1
4CompletedTreatmentAtherosclerosis / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Dyslipidemias / Strokes1
4CompletedTreatmentAtherosclerosis / High Blood Cholesterol Level1
4CompletedTreatmentBMI >30 kg/m2 / Cardiovascular Disease (CVD) / Hypertriglyceridemias / Lipid Disorders1
4CompletedTreatmentBronchiectasis2
4CompletedTreatmentCVD1
4CompletedTreatmentCardiovascular Disease (CVD)2
4CompletedTreatmentCardiovascular Disease (CVD) / Dyslipidemias / High Blood Cholesterol Level1
4CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / Myocardial Diseases / Myocardial Ischemia / Prophylaxis of cardiomyopathy1
4CompletedTreatmentCardiovascular Disease (CVD) / Ischemia Reperfusion Injury1
4CompletedTreatmentCerebrovascular Accidents / Coronary Arteriosclerosis / Dyslipidemias / Peripheral Vascular Disease (PVD) / Type 2 Diabetes Mellitus2
4CompletedTreatmentCerebrovascular Accidents / High Blood Cholesterol Level1
4CompletedTreatmentChronic Kidney Disease (CKD)1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentChronic Periaortitis / Intrabony Periodontal Defect1
4CompletedTreatmentChronic Stable Angina Pectoris / Non ST Segment Elevation Myocardial Infarction (NSTEMI) / Unstable Angina Pectoris1
4CompletedTreatmentCongestive Heart Failure (CHF)1
4CompletedTreatmentCoronary Arteriosclerosis1
4CompletedTreatmentCoronary Arteriosclerosis / High Blood Cholesterol Level2
4CompletedTreatmentCoronary Artery Bypass Surgery / Elective Surgical Procedure1
4CompletedTreatmentCoronary Artery Disease1
4CompletedTreatmentCoronary Artery Disease / High Blood Cholesterol Level3
4CompletedTreatmentCoronary Artery Disease / Hyperlipidemias1
4CompletedTreatmentCoronary Heart Disease (CHD) / High Blood Cholesterol Level2
4CompletedTreatmentDiabetes Mellitus (DM)1
4CompletedTreatmentDiabetes, Diabetes Mellitus Type 1 / Dyslipidemias1
4CompletedTreatmentDyslipidemia (Fredrickson Type Ⅱa)1
4CompletedTreatmentDyslipidemia in Patients With Diabetes Mellitus1
4CompletedTreatmentDyslipidemias7
4CompletedTreatmentDyslipidemias / High Blood Pressure (Hypertension)3
4CompletedTreatmentHIV Dementia2
4CompletedTreatmentHealthy Volunteers2
4CompletedTreatmentHeart Failure, Unspecified1
4CompletedTreatmentHepatitis C Viral Infection1
4CompletedTreatmentHigh Blood Cholesterol Level10
4CompletedTreatmentHigh Blood Cholesterol Level / High Blood Pressure (Hypertension)1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Hyperlipidemias1
4CompletedTreatmentChronic, stable Kidney Disease / High Blood Pressure (Hypertension)1
4CompletedTreatmentHypercholesterolemia With Type2DM1
4CompletedTreatmentHyperlipidemias1
4CompletedTreatmentHypertriglycemia / Type 2 Diabetes Mellitus1
4CompletedTreatmentMetabolic Syndromes1
4CompletedTreatmentMulti-vessel Diseases, Angina1
4CompletedTreatmentMyocardial Infarction / Reperfusion Injury1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentStable Angina (SA)1
4CompletedTreatmentStroke, Ischemic2
4CompletedTreatmentType 2 Diabetes Mellitus2
4CompletedTreatmentType IIa and IIb Hypercholesterolaemia1
4CompletedTreatmentVascular Surgery1
4CompletedTreatmentTransient ischemia attacks1
4Enrolling by InvitationPreventionDisability Free Survival / Elderly / Healthy Volunteers / Independent Living1
4Enrolling by InvitationTreatmentCerebral Infarctions / CLOPIDOGREL, POOR METABOLISM of (Disorder)1
4Enrolling by InvitationTreatmentChronic Total Occlusion of Coronary Artery / Coronary Artery Disease / Percutaneous Coronary Intervention / Viable Myocardium1
4Enrolling by InvitationTreatmentComplete Occlusion of Coronary Artery / Hibernation, Myocardial1
4Not Yet RecruitingDiagnosticCoronary Artery Disease1
4Not Yet RecruitingPreventionCardiovascular Disease (CVD)2
4Not Yet RecruitingTreatmentCarotid Artery Stenosis1
4Not Yet RecruitingTreatmentCoronary Artery Disease2
4RecruitingDiagnosticHyperlipidemias1
4RecruitingOtherCardiovascular Disease (CVD)1
4RecruitingOtherHigh Blood Cholesterol Level1
4RecruitingPreventionAcute Coronary Syndromes (ACS)1
4RecruitingPreventionAdverse Effects / Cardiovascular Disease (CVD) / Hyperlipidemias1
4RecruitingPreventionArrythmias1
4RecruitingPreventionCardiothoracic Surgery / Post-Operative Atrial Fibrillation1
4RecruitingPreventionCoronary Artery Disease1
4RecruitingPreventionHepatocellular,Carcinoma1
4RecruitingPreventionHigh Blood Pressure (Hypertension) / Strokes / Transient Ischaemic Attack (TIA)1
4RecruitingPreventionMitochondrial Diseases1
4RecruitingTreatmentAngina, Prinzmetal's1
4RecruitingTreatmentArterial Hypertension / Blood Pressures / Dyslipidemias / Lipid Metabolism Disorders1
4RecruitingTreatmentCardiovascular Disease (CVD)1
4RecruitingTreatmentCoronary Artery Disease1
4RecruitingTreatmentDental Plaque1
4RecruitingTreatmentDiabetes Mellitus (DM) / Dyslipidemias / Fatty Liver1
4RecruitingTreatmentDiabetes Mellitus Type 2 Platelets Reactivity Statin1
4RecruitingTreatmentDyslipidemias / High Blood Pressure (Hypertension) / Prediabetic State1
4RecruitingTreatmentHeart Failure, Unspecified1
4RecruitingTreatmentMyocardial Infarction1
4RecruitingTreatmentSevere Hypercholesterolemia1
4RecruitingTreatmentSocket Preservation1
4SuspendedPreventionCardiovascular Disease (CVD) / Osteoarthritis (OA)1
4TerminatedNot AvailableHypertension and Cardiovascular Risk Factors1
4TerminatedNot AvailableStatin Adverse Reaction / Statin-Associated Myopathy1
4TerminatedDiagnosticMyopathic Conditions1
4TerminatedPreventionAtherosclerosis / Carotid Artery Stenosis / Strokes1
4TerminatedPreventionCoarctation of the Aorta1
4TerminatedPreventionCoronary Heart Disease (CHD)1
4TerminatedPreventionHigh Blood Pressure (Hypertension)1
4TerminatedTreatmentAortic Valve Stenosis1
4TerminatedTreatmentAtherosclerosis / Coronary Artery Disease / High Blood Cholesterol Level1
4TerminatedTreatmentChronic Kidney Disease (CKD) / High Blood Cholesterol Level1
4TerminatedTreatmentHigh Blood Cholesterol Level1
4TerminatedTreatmentHyperlipidemias / Non-Insulin Dependent Diabetes Mellitus / Type 2 Diabetes Mellitus1
4TerminatedTreatmentStable Angina (SA)1
4Unknown StatusNot AvailableCoronary Heart Disease (CHD) / Diabetes Mellitus (DM) / High Blood Cholesterol Level / Non-Coronary Atherosclerotic Disease1
4Unknown StatusPreventionCarotid Stenosis1
4Unknown StatusPreventionCholesterol, HDL1
4Unknown StatusPreventionCoronary Heart Disease (CHD)1
4Unknown StatusPreventionEndothelium / Hydroxymethylglutaryl-CoA Reductase Inhibitors1
4Unknown StatusPreventionGeneral Surgery / Prevention / Thrombosis1
4Unknown StatusPreventionVaccination Failure / Viral Hepatitis B1
4Unknown StatusTreatmentAcute Coronary Syndromes (ACS)1
4Unknown StatusTreatmentAngina Pectoris, Variant1
4Unknown StatusTreatmentAnterior Acute Myocardial Infarction1
4Unknown StatusTreatmentArterial and Arteriolar Disorders1
4Unknown StatusTreatmentAtherosclerosis1
4Unknown StatusTreatmentAtherosclerosis / Inflammatory Reaction1
4Unknown StatusTreatmentCoronary Artery Disease3
4Unknown StatusTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
4Unknown StatusTreatmentDiabetes Mellitus, Hypercholessterolemia1
4Unknown StatusTreatmentDrug-eluting Stent (DES)1
4Unknown StatusTreatmentFocus of Study1
4Unknown StatusTreatmentHigh Blood Pressure (Hypertension)1
4Unknown StatusTreatmentMyocardial Infarction / Unstable Angina (UA)1
4Unknown StatusTreatmentST Elevation Myocardial Infarction (STEMI)1
4Unknown StatusTreatmentType 2 Diabetes Mellitus Without Insulin Treatment1
4WithdrawnTreatmentAngina Pectoris, Variant / Statins, HMG-CoA1
4WithdrawnTreatmentAtherosclerosis1
Not AvailableActive Not RecruitingTreatmentRheumatoid Arthritis1
Not AvailableCompletedNot AvailableAngina Pectoris / Dyslipidemia (Fredrickson Type Ⅱa) / High Blood Cholesterol Level / High Blood Pressure (Hypertension)1
Not AvailableCompletedNot AvailableAtheroma / Atherosclerosis / Atherosclerotic Carotid Disease1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Coronary Artery Disease1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableCarotid Atherosclerosis / Metabolic Syndromes / Strokes / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableCongestive Cardiomyopathy1
Not AvailableCompletedNot AvailableEndothelial Function / Infection NOS / Inflammatory Reaction1
Not AvailableCompletedNot AvailableGynecologic Oncological Pelvic/Abdominal Surgery1
Not AvailableCompletedNot AvailableHigh Blood Cholesterol Level3
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)1
Not AvailableCompletedNot AvailableHydroxymethylglutaryl-CoA Reductase Inhibitors / Muscular Diseases1
Not AvailableCompletedBasic ScienceDifference of 12-hour AUC1
Not AvailableCompletedBasic ScienceHydroxymethylglutaryl-CoA Reductase Inhibitors / Type 2 Diabetes Mellitus1
Not AvailableCompletedBasic ScienceHyperlipidemias1
Not AvailableCompletedDiagnosticCoronary Artery Disease / High Blood Cholesterol Level / Monocyte Function1
Not AvailableCompletedPreventionAcute Kidney Injury (AKI)1
Not AvailableCompletedPreventionAcute Kidney Injury (AKI) / Acute Renal Failure (ARF) / Delirium / Icu Delirium / Post-Operative Delirium1
Not AvailableCompletedPreventionArrythmias1
Not AvailableCompletedPreventionCoronary Artery Bypass Graft1
Not AvailableCompletedPreventionInflammatory Reaction / Myocardial Infarction / Myocardial Ischemia1
Not AvailableCompletedPreventionBone destruction1
Not AvailableCompletedTreatmentAngioplasty, Transluminal, Percutaneous Coronary1
Not AvailableCompletedTreatmentAtherosclerosis1
Not AvailableCompletedTreatmentAtherosclerosis / Cardiovascular Disease (CVD) / Human Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections / Inflammatory Reaction / Statins, HMG-CoA1
Not AvailableCompletedTreatmentCardiovascular Disease (CVD)1
Not AvailableCompletedTreatmentChronic Kidney Disease (CKD)1
Not AvailableCompletedTreatmentChronic Kidney Disease (CKD) / Proteinuria1
Not AvailableCompletedTreatmentCoronary Arteriosclerosis / Genetic Diseases, Inborn / Hypoalphalipoproteinemias1
Not AvailableCompletedTreatmentCoronary Artery Disease1
Not AvailableCompletedTreatmentDiastolic Heart Failure1
Not AvailableCompletedTreatmentEnd-Stage Renal Disease (ESRD)1
Not AvailableCompletedTreatmentHealthy Volunteers2
Not AvailableCompletedTreatmentHigh Blood Cholesterol Level / High Blood Pressure (Hypertension)1
Not AvailableCompletedTreatmentHypercholesterolemia With Concomitant Type 2 Diabetes1
Not AvailableCompletedTreatmentHyperlipidemias1
Not AvailableCompletedTreatmentPolycystic Ovaries Syndrome1
Not AvailableCompletedTreatmentShock, Septic1
Not AvailableCompletedTreatmentThoracic Surgery1
Not AvailableNot Yet RecruitingPreventionPsoriatic Arthritis / Rheumatoid Arthritis1
Not AvailableRecruitingNot AvailableCoronary Arteriosclerosis / Coronary Artery Disease / Hydroxymethylglutaryl-CoA Reductase Inhibitors1
Not AvailableRecruitingBasic ScienceAtherosclerosis / Cardiovascular Disease (CVD)1
Not AvailableRecruitingTreatmentGlomerulonephritis minimal lesion1
Not AvailableRecruitingTreatmentSleep Deprivation1
Not AvailableTerminatedBasic ScienceDiabetes Mellitus (DM) / Metabolic Syndromes1
Not AvailableTerminatedPreventionRenal Dysfunction1
Not AvailableTerminatedTreatmentCoronary Artery Disease1
Not AvailableTerminatedTreatmentDiastolic Heart Failure1
Not AvailableUnknown StatusNot AvailableDisseminated Sclerosis1
Not AvailableUnknown StatusBasic ScienceAutonomic Changes of Cardiomyocytes Repolarisation / Heterogeneity of Cardiomyocytes Repolarisation1
Not AvailableUnknown StatusDiagnosticDiabetes Mellitus (DM)1
Not AvailableUnknown StatusPreventionAtherosclerosis1
Not AvailableUnknown StatusTreatmentAcute Coronary Syndromes (ACS)2
Not AvailableUnknown StatusTreatmentBlood Pressure Variability / Intracranial Artery Stenosis1
Not AvailableUnknown StatusTreatmentCongestive Heart Failure (CHF)1
Not AvailableUnknown StatusTreatmentCoronary Artery1
Not AvailableUnknown StatusTreatmentEndometriosis / Pain1
Not AvailableUnknown StatusTreatmentHigh Blood Cholesterol Level / Thrombosis1
Not AvailableUnknown StatusTreatmentNonalcoholic Fatty Liver Disease (NAFLD)1
Not AvailableUnknown StatusTreatmentMixed hypercholesterolemia1
Not AvailableWithdrawnBasic ScienceNeurocognitive Dysfunction1
Not AvailableWithdrawnTreatmentAtherosclerosis / Type 2 Diabetes Mellitus1
Not AvailableWithdrawnTreatmentComplication of Renal Dialysis1
Not AvailableWithdrawnTreatmentEndothelial Dysfunction1
Not AvailableWithdrawnTreatmentNon Alcoholic Fatty Liver Diseases (NAFLD)1
Not AvailableWithdrawnTreatmentRecurrent Prostate Cancer / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Bryant Ranch Prepack
  • Cardinal Health
  • Direct Pharmaceuticals Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Goedecke GmbH
  • Healthcare Pharmacy
  • Heartland Repack Services LLC
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nucare Pharmaceuticals Inc.
  • Orifice Medical AB
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Southwood Pharmaceuticals
  • Tya Pharmaceuticals
  • US Pharmaceutical Group
  • Vangard Labs Inc.
  • Vitrum Ab
  • Warner Lambert Company LLC
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
Tablet, film coatedOral10 mg/301
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral20 mg/301
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral80 mg/301
Tablet, film coatedOral80 mg/1
TabletOral
Tablet, film coatedOral
TabletOral10 mg
TabletOral20 mg
TabletOral40 mg
TabletOral80 mg
Prices
Unit descriptionCostUnit
Lipitor 20 mg tablet5.0USD tablet
Lipitor 40 mg tablet5.0USD tablet
Lipitor 80 mg tablet5.0USD tablet
Lipitor 10 mg tablet3.5USD tablet
Lipitor 40 mg Tablet2.52USD tablet
Lipitor 80 mg Tablet2.52USD tablet
Lipitor 20 mg Tablet2.34USD tablet
Lipitor 10 mg Tablet1.87USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4681893No1992-09-242009-09-24Us
CA2521776No2006-04-252022-05-21Canada
CA2220018No2001-04-172016-07-08Canada
US5969156Yes1997-01-082017-01-08Us
USRE42461Yes1997-04-252017-04-25Us
US6455574No1998-08-112018-08-11Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)159.2-160.7 °CNot Available
water solubilitySodium salt soluble in water, 20.4 ug/mL (pH 2.1), 1.23 mg/mL (pH 6.0)Not Available
logP5.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00063 mg/mLALOGPS
logP4.24ALOGPS
logP5.39ChemAxon
logS-6ALOGPS
pKa (Strongest Acidic)4.33ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area111.79 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity158.2 m3·mol-1ChemAxon
Polarizability59.39 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8947
Blood Brain Barrier-0.7825
Caco-2 permeable-0.8956
P-glycoprotein substrateSubstrate0.5246
P-glycoprotein inhibitor IInhibitor0.7164
P-glycoprotein inhibitor IIInhibitor0.8724
Renal organic cation transporterNon-inhibitor0.8131
CYP450 2C9 substrateNon-substrate0.7887
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6841
CYP450 1A2 substrateNon-inhibitor0.8551
CYP450 2C9 inhibitorNon-inhibitor0.719
CYP450 2D6 inhibitorNon-inhibitor0.9042
CYP450 2C19 inhibitorNon-inhibitor0.6191
CYP450 3A4 inhibitorNon-inhibitor0.6675
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6894
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7777
BiodegradationNot ready biodegradable0.9974
Rat acute toxicity2.5686 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9904
hERG inhibition (predictor II)Non-inhibitor0.5101
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0a4i-0000090000-ae5c999b091a2bc93933
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0a4i-0000190000-dd563e18b1f0f74aadd5
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0zfs-0007960000-cb66a18d2f0a687261ba
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-002b-0059000000-0942bc1e35434cd7d0d3
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-004i-0093000000-f42ba46820a3cf3295c5
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udj-0005910000-b09ba5f3b86948c7f3cb
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0000090000-6f297ca79ae1761aac33
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-1009300000-9479520f395dcdd585e7
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0092000000-9b561b8d35c3bdc5e46a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0090000000-3aad87273e7f9942a50f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-01t9-1090000000-3f0efff41ebdb5320ce4
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-2090000000-0227638704b90c4249d0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0000090000-65c729c6734f6533c431
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-1009300000-9122e4479d8c0c32bb0d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0092000000-22d639a8882509e1bcdb
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0090000000-30a0198165bae85fa258
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-01t9-1090000000-cb3feea45f5280f05c37
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-2090000000-8db2f70b373277f143c0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udj-0005910000-a63c845ca248d958068d
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a6s-1085190000-9e43612012842effca5a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0031900000-4081fba1ae61b0d871cf
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-052f-0000980000-6751fefdee0a257e52f8
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0000900000-4009a70e947dcceb6e0f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0085900000-e1a4447e4c9a4bda83b2
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0092100000-4a5517154ad5f7375ea2
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0000090000-e741fcb91eb29d1032cb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00kf-0000900000-fdd41dae94afd3f4d3c5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0000490000-25199beeece682c7de9e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0020900000-71cacdfc979c4386762b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0092000000-38374b1412250df34777
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0090000000-87710909ebad67c88f3b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udj-0190000000-60e7ef3dc3f76db11c5f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f72-0290000000-e8c2cda8588874b2aaa5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0000490000-a5ee6b466e73e9e72383
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0011900000-b8fc562d4be5ffb07f59
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0092000000-df78998b01951a3dd03a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0090000000-19c391db652668c97d59
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udj-0190000000-931a1911dcd7ec9dbbc8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f72-0290000000-6157ef91cb98aeef5cf7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00kf-0000900000-cd6fb2c00146543cbb47
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f6x-0092420000-fb2c084ecdd5af8f6f7b

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylpyrroles. These are aromatic heterocyclic compounds with a structure based on a pyrrole ring linked to exactly two phenyl groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrroles
Sub Class
Substituted pyrroles
Direct Parent
Diphenylpyrroles
Alternative Parents
Aromatic anilides / Medium-chain hydroxy acids and derivatives / Pyrrole carboxamides / Medium-chain fatty acids / Beta hydroxy acids and derivatives / Fluorobenzenes / Halogenated fatty acids / Hydroxy fatty acids / Heterocyclic fatty acids / Aryl fluorides
show 13 more
Substituents
2,3-diphenylpyrrole / Aromatic anilide / Medium-chain hydroxy acid / Pyrrole-3-carboxamide / Pyrrole-3-carboxylic acid or derivatives / Medium-chain fatty acid / Beta-hydroxy acid / Fluorobenzene / Halobenzene / Halogenated fatty acid
show 30 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
statin (synthetic), aromatic amide, pyrroles, dihydroxy monocarboxylic acid, monofluorobenzenes (CHEBI:39548)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Nadph binding
Specific Function
Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including...
Gene Name
HMGCR
Uniprot ID
P04035
Uniprot Name
3-hydroxy-3-methylglutaryl-coenzyme A reductase
Molecular Weight
97475.155 Da
References
  1. Davidson MH: Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 2002 Mar;11(3):125-41. [PubMed:12769127]
  2. Jafari M, Ebrahimi R, Ahmadi-Kashani M, Balian H, Bashir M: Efficacy of alternate-day dosing versus daily dosing of atorvastatin. J Cardiovasc Pharmacol Ther. 2003 Jun;8(2):123-6. [PubMed:12808485]
  3. Baxter JD, Webb P, Grover G, Scanlan TS: Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight. Trends Endocrinol Metab. 2004 May-Jun;15(4):154-7. [PubMed:15109613]
  4. Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y: Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun. 2004 Nov 12;324(2):835-9. [PubMed:15474503]
  5. Bosel J, Gandor F, Harms C, Synowitz M, Harms U, Djoufack PC, Megow D, Dirnagl U, Hortnagl H, Fink KB, Endres M: Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem. 2005 Mar;92(6):1386-98. [PubMed:15748157]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Virus receptor activity
Specific Function
Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by bindi...
Gene Name
DPP4
Uniprot ID
P27487
Uniprot Name
Dipeptidyl peptidase 4
Molecular Weight
88277.935 Da
References
  1. Taldone T, Zito SW, Talele TT: Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin. Bioorg Med Chem Lett. 2008 Jan 15;18(2):479-84. Epub 2007 Dec 3. [PubMed:18068977]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Transcription regulatory region dna binding
Specific Function
Ligand-activated transcriptional activator. Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes...
Gene Name
AHR
Uniprot ID
P35869
Uniprot Name
Aryl hydrocarbon receptor
Molecular Weight
96146.705 Da
References
  1. Hu W, Sorrentino C, Denison MS, Kolaja K, Fielden MR: Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol Pharmacol. 2007 Jun;71(6):1475-86. Epub 2007 Feb 27. [PubMed:17327465]
  2. Chauvin B, Drouot S, Barrail-Tran A, Taburet AM: Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013 Oct;52(10):815-31. doi: 10.1007/s40262-013-0075-4. [PubMed:23703578]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81. [PubMed:17178259]
  2. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U: Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000 Nov;28(11):1369-78. [PubMed:11038166]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U: Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000 Nov;28(11):1369-78. [PubMed:11038166]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U: Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000 Nov;28(11):1369-78. [PubMed:11038166]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Stormo C, Bogsrud MP, Hermann M, Asberg A, Piehler AP, Retterstol K, Kringen MK: UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7. doi: 10.1007/s40291-013-0031-x. [PubMed:23580084]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Stormo C, Bogsrud MP, Hermann M, Asberg A, Piehler AP, Retterstol K, Kringen MK: UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7. doi: 10.1007/s40291-013-0031-x. [PubMed:23580084]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang E, Casciano CN, Clement RP, Johnson WW: HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 2001 Jun;18(6):800-6. [PubMed:11474784]
  2. Sieczkowski E, Lehner C, Ambros PF, Hohenegger M: Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer. 2010 May 1;126(9):2025-35. doi: 10.1002/ijc.24885. [PubMed:19739078]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278]
  2. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22. [PubMed:15970799]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG: Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010 Feb 5;106(2):297-306. doi: 10.1161/CIRCRESAHA.109.203596. Epub 2009 Nov 25. [PubMed:19940267]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name
ABCC5
Uniprot ID
O15440
Uniprot Name
Multidrug resistance-associated protein 5
Molecular Weight
160658.8 Da
References
  1. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG: Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010 Feb 5;106(2):297-306. doi: 10.1161/CIRCRESAHA.109.203596. Epub 2009 Nov 25. [PubMed:19940267]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG: Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010 Feb 5;106(2):297-306. doi: 10.1161/CIRCRESAHA.109.203596. Epub 2009 Nov 25. [PubMed:19940267]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, Bohm M, Felix SB, Vogelgesang S, Jedlitschky G, Siegmund W, Warzok R, Kroemer HK: Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther. 2006 Dec;80(6):607-20. [PubMed:17178262]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Klatt S, Fromm MF, Konig J: The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members. Basic Clin Pharmacol Toxicol. 2013 Apr;112(4):244-50. doi: 10.1111/bcpt.12031. Epub 2012 Dec 6. [PubMed:23121773]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Becker ML, Elens LL, Visser LE, Hofman A, Uitterlinden AG, van Schaik RH, Stricker BH: Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. Pharmacogenomics J. 2013 Jun;13(3):251-6. doi: 10.1038/tpj.2011.59. Epub 2011 Dec 20. [PubMed:22186618]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 10:01